News HitGen Inc.

Equities

688222

CNE1000040G3

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-06-05 pm EDT			5-day change	1st Jan Change
11.35 ^CNY	-5.73%		-8.17%	-24.28%

Apr. 24	HitGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Feb. 23	HitGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HitGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24	CI
HitGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
HitGen Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Chengdu HitGen and the Structural Genomics Consortium have reached A Cooperation in the research and development of new drugs based on DEL technology Release time, 2023-09-28	23-09-29	AQ
HitGen Receives 10 Million Yuan in Government Subsidies	23-09-29	MT
The Structural Genomics Consortium and HitGen Inc. Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery	23-09-28	CI
Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology	23-09-26	AQ
HitGen Inc.(XSSC:688222) added to S&P Global BMI Index	23-09-18	CI
HitGen Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-22	CI
Chengdu Hittech and Nested Therapeutics signed a new drug research and development service contract based on DEL technology	23-08-11	AQ
HitGen Inc. Enters into DNA-Encoded Library Based Research Service Agreement with Nested Therapeutics, Inc	23-08-10	CI
HitGen Inc. Launches A Newly Upgraded Version of OpenDELâ„¢, A Self-Service Screening Kit, to Facilitate Innovative Drug Discovery Research	23-06-26	CI
HitGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Certain A Shares of HitGen Inc. are subject to a Lock-Up Agreement Ending on 16-APR-2023.	23-04-15	CI
HitGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Tranche Update on HitGen Inc.'s Equity Buyback Plan announced on July 1, 2022.	22-12-29	CI
HitGen Inc.'s Equity Buyback announced on July 1, 2022, has expired with 1,238,700 shares, representing 0.34% for CNY 20 million.	22-12-28	CI
HitGen Inc. Announces Research Agreement with Nitrase Therapeutics, Inc. Focused on DNA-Encoded Library Based Drug Discovery	22-12-11	CI
DAEWOONG PHARMACEUTICAL Co., Ltd and HitGen Inc. Announces Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery	22-11-13	CI
HitGen Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News HitGen Inc.

Equities

688222

CNE1000040G3

Summary

Filters